Key Points:
• Germline, gain-of-function mutations in STAT3 lead to lymphoproliferation and autoimmunity with prominent cytopenias.
• Mutations in STAT3 cause altered regulatory T cells and cytokine signaling. suggesting a potential therapeutic option for such patients. These results suggest that there is a broad range of autoimmunity caused by germline STAT3 gain-of-function mutations, and that hematologic autoimmunity is a major component of this newlydescribed disorder. Some patients for this study were enrolled in a trial registered at ClinicalTrials.gov #NCT00001350.
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Introduction
The control of lymphocyte proliferation and tolerance are essential for both host defense and protection against self-directed immune attack. The discovery of autoimmune disorders with Mendelian inheritance that lead to a loss of tolerance has provided critical insights into biologic pathways important for regulation of the human immune response.
For example, disorders of Fas-mediated apoptosis perturb peripheral lymphocyte tolerance and lead to the lymphoproliferation and hematologic autoimmunity seen in autoimmune lymphoproliferative syndrome (ALPS). 1, 2 Similarly, mutations in genes important for the development and/or function of regulatory T cells dramatically undermine peripheral tolerance, producing early-onset, polyendocrine autoimmunity and immune dysregulation as seen in immunodeficiency polyendocrinopathy enteropathy xlinked (IPEX) and IPEX-like disorders. 3 Mutations in AIRE, important for central T cell tolerance, lead to a less severe syndrome of multiendocrine autoimmunity and mucocutaneous candidiasis called autoimmune polyendocrinopathy candidiasis and ectodermal dysplasia (APECED). 4, 5 An improved understanding of the mechanisms which regulate immune tolerance has the potential to improve the treatment of common autoimmune disorders by identifying and then targeting the relevant cellular pathways.
To further this process of discovery, we performed whole exome sequencing of DNA from patients with early-onset autoimmunity and lymphoproliferative disease reminiscent of ALPS without a known genetic cause. We identified heterozygous STAT3 mutations in thirteen individuals from ten families, consistent with an apparent autosomal dominant inheritance in certain kindreds and sporadic occurrences in others.
Recently, a series of five patients with germline mutations in STAT3 associated
For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From predominantly with neonatal diabetes was reported by Flanagan et al., 6 consistent with the hypothesis that such mutations can cause autoimmune disease. Here we present genetic and functional data that reveal dysregulated cytokine signaling due to gain-offunction STAT3 mutations with important implications for understanding lymphocyte tolerance and the pathogenesis of systemic autoimmunity.
Methods

Patients
Participants were enrolled independently at each institution into research studies utilizing whole exome sequencing to identify genetic causes of autoimmunity. Written and informed consent was obtained for living patients and their family members. These studies were approved by the Institutional Review Boards of the authors' institutions.
Patients 2-4 and Family 1 were enrolled in ClinicalTrials.gov identifier NCT00001350.
Whole exome sequencing
Genomic DNA was extracted from whole blood or saliva and coding regions enriched (SureSelect All Exon, Agilent Technologies, Santa Clara, CA or as described 7 
Expression plasmids
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Primers used are reported in Table S1 
Detection of T cell subsets
Flow cytometry was conducted on patient samples at four separate facilities. Typically, PBMCs were isolated by density centrifugation and resuspended in RPMI1640 supplemented with penicillin, streptomycin and L-glutamine along with 10% FCS. 
EBV-transformed cell lines and phosphoflow
EBV-transformed lymphoblastoid cell lines were generated from available 
Statistics
Results were analyzed with Mann-Whitney or unpaired two-tailed Student t test using Graph-pad Prism software and P<.05 considered statistically significant.
Results
Whole exome sequencing identifies STAT3 variants in patients with lymphoproliferation and early-onset autoimmune disease.
Whole exome sequencing was performed at multiple centers on a cohort of patients with prominent lymphoproliferation, including lymphadenopathy and/or hepatosplenomegaly, as well as early-onset, multi-system autoimmunity for whom a genetic diagnosis had not been established (Table 1) . Upon comparing results in a subset of the cohort, it was noted that mutations in STAT3 were observed in thirteen patients from ten families (Tables 1 and S2 ). All were missense variants that were predicted to be deleterious by a variety of algorithms (Table S2) . Interestingly, this same mutation was observed in a patient with early-onset type I diabetes. 6 In contrast to the recently reported patients with STAT3 mutations who predominantly had type I diabetes and enteropathy, 6 within our cohort hematologic autoimmunity was most prevalent including autoimmune hemolytic anemia,
For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From neutropenia, and/or thrombocytopenia (Table 1) . Similar solid organ autoimmunity was present in some of our patients, including autoimmune enteropathy (Table S3) . Others also exhibited arthritis, lung disease consistent with lymphocytic interstitial pneumonia, hepatitis, atopic dermatitis, alopecia and/or scleroderma.
Several patients also had recurrent and/or severe infections (Table 2) , which was not a prominent feature of the five patients recently reported. 6 We noted four patients with fungal infections. Whether this particular finding may become more common as more patients are described with this disorder remains to be seen. In several of the patients with recurrent infections, hypogammaglobulinemia was noted (Table 2 ) but only Patient 4 fulfilled criteria for common variable immune deficiency (Table S4 ). Of note, the chronic immune suppression required in these patients has the potential to cause some, but not all of these phenotypes.
Similar to the previously reported patients 6 , we noted post-natal short stature <5% percentile in a majority of our patients (7/13 patients). Several patients exhibited profound growth failure as represented by their growth curves ( Figure S1A -D). The growth hormone axis was assessed in three patients; two patients were treated with growth hormone with good response (Table S5) .
Additional immunologic laboratory features among our cohort were variable but included moderate T cell lymphopenia, hypogammaglobulinemia, and elevated double negative (CD4 neg CD8 neg ) CD3 + TCRα/β + T cells (DNTs) in many patients ( Table 2 ). The observation of elevated DNTs is a consistent feature of ALPS and FAS pathway defects, but has also been observed in pediatric patients with more common autoimmune diseases and likely reflects a lymphoproliferative state. 1,2,10 FAS-mediated
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In two families (Patient 4 and Family 1), there were family members carrying a STAT3 mutation who had a less severe phenotype or were asymptomatic (father of Patient 4, not included here). In Family 1, Patient 11 experienced a single, childhood episode of lymphoproliferation and hematologic autoimmunity which resolved without sequelae. A third sibling in Family 1 also carries the STAT3 mutation but is asymptomatic. Therefore, not only is the clinical phenotype of these patients diverse as described above, there appear to be carriers of these mutations who display incomplete penetrance.
The observed STAT3 mutations lead to enhanced transcriptional activity but not constitutive phosphorylation of STAT3.
STAT3 encodes signal transducer and activator of transcription 3, one of a family of transcription factors that play critical roles in affecting cytokine-induced changes in gene expression. [11] [12] [13] Following receptor ligation, JAK kinases recruit, phosphorylate, and activate STATs. STATs then translocate to the nucleus and interact with specific DNA elements as part of transcriptional regulatory complexes, which, depending on the cytokine and STAT molecule involved, can promote both pro-and anti-inflammatory pathways.
The stereotyped clinical phenotype of our patient cohort with multisystem autoimmunity and lymphoproliferation as described above and further in Table S7 was quite distinct from that associated with germline STAT3 mutations shown to confer a For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From loss-of-function (i.e., hyper-IgE syndrome). 14, 15 Analogous to the contrasting allelic disorders caused by gain-and loss-of-function mutations in STAT1, 13, 16, 17 we hypothesized that the changes observed here in STAT3 lead to a gain-of-function.
Mechanistically, gain-of-function STAT3 mutations could be predicted to lead to autoimmunity because of the known involvement of STAT3 in intracellular signaling pathways relevant to immune dysregulation, including proinflammatory signaling and inhibition of Treg and enhancement of Th17 cell fate determination. 18-21 Furthermore, somatic, gain-of-function STAT3 mutations are reported in association with large granular lymphocytic leukemias and acquired aplastic anemia, both of which involve a prominent autoimmune component. 8, 22 Indeed, the recent series of five patients with autoimmunity and STAT3 mutations included evidence that the mutations conferred a gain-of-function. 6 To test the effect of the mutations found in our cohort on STAT3 function, constructs containing the variants were transfected into a STAT3-deficient cell line (A4 cells). 9 Each variant produced detectable immunoreactivity via Western blot ( Figure 1B 
patients with gain-of-function mutations in STAT3 was reportedly reduced. 6 Analysis of peripheral blood cells from our patients within the same institution ( Figure 4A ) showed diminished numbers of Treg cells as well as decreased expression of CD25, which is required for Treg function ( Figure 4B&C ). Two additional patients examined at other institutions also exhibited decreased expression of FOXP3 and/or CD25 ( Figure S7 ).
Peripheral blood mononuclear cells from a patient with a gain-of-function STAT3
mutation exhibit delayed kinetics of de-phosphorylation.
The mechanism by which STAT3 gain-of-function produces downstream effects such as increased SOCS3 transcription could not be explained by hyper-phosphorylation ( Figure   S3 ), as has been reported for gain-of-function mutations in STAT1. 17 However, after stimulation with IL-6, PBMCs from Patient 1 exhibited delayed de-phosphorylation of pSTAT3 compared to healthy controls ( Figure S8 ). This may provide an alternative explanation for increased STAT3 activity in some of these patients.
Two patients with germline, gain-of-function STAT3 mutations received hematopoietic stem cell transplants.
All of the symptomatic patients reported here required significant immunosuppression to control their autoimmune diseases and two patients (Patients 7 and 8) underwent hematopoietic stem cell transplantation (HSCT) for refractory autoimmunity as detailed in 
Discussion
Here we describe gain-of-function STAT3 mutations in a cohort of patients with lymphoproliferation and childhood-onset autoimmunity. We demonstrate that these mutations confer increased STAT3 transcriptional activity, impair cytokine signaling via other STAT molecules, and diminish the Treg compartment.
Our findings further support a role for human STAT3 in immune regulation and extend the spectrum of STAT3-associated disease. Patients bearing germline, loss-offunction STAT3 mutations have immunodeficiency and exhibit infections quite distinct from those observed in this cohort, along with impaired Th17 differentiation, markedly higher levels of IgE, and far more common connective tissue abnormalities. 14, 15, 21 Somatic, gain-of-function mutations in STAT3 are associated with lymphoproliferative neoplasms, acquired aplastic anemia, and myelodysplastic syndrome, but again, appear to be distinct from the phenotype in this cohort, especially given the relative dearth of neoplastic disease among these patients with congenital gain-of-function mutations. 8, 11, 22 While this cohort shares common clinical characteristics, including autoimmune cytopenias, lymphoproliferation, and short stature, affected individuals varied in their age at presentation and extent of solid organ autoimmunity. This could also be related to a defect in Treg function, which we are not able to assess due to leukopenia and decreased surface expression of CD25, which have precluded sorting the CD25 + Treg population in our patients.
The mechanism underlying the gain-of-function in STAT3 has not yet been In summary, we describe a relatively large cohort of patients with a monogenic disorder of early-onset autoimmunity and lymphoproliferation caused by gain-offunction, germline STAT3 mutations. These findings significantly expand the clinical For personal use only. on April 13, 2017. by guest www.bloodjournal.org From spectrum of this newly-described monogenic disorder and provide evidence for a potential mechanism whereby this gain-of-function leads to altered immune cell tolerance via interference with the activation of other STAT molecules. These findings suggest a broad range of autoimmune and lymphoproliferative disorders may be explained by inborn errors of cytokine signaling. They also provide a new model for studying the biology and clinical consequences of the complex regulatory networks involved in STAT-mediated signaling. Furthermore, we provide a rationale for the use of inhibitors of this pathway, including anti-IL-6R therapy as shown here, or, potentially, small molecule inhibitors of STAT3, to achieve substantial therapeutic benefit in this and related conditions. Louis, MO, USA 63110, e-mail: cooper_m@kids.wustl.edu.
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